Vineti Stock
Vineti is a pioneering cell and gene therapy software and analytics company.
About Vineti Stock
Vineti is the first commercial cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of 21st century medicine. The Vineti platform integrates logistics, manufacturing and clinical data to improve product performance overall. Caregivers and pharmaceutical pioneers are empowered to help more patients more effectively and safely, treatments are better understood and improved over time, and most importantly, there’s an opportunity to provide greater health outcomes—and cures—to patients in need.
Funding History
| June 2017 | $13.8M |
|---|---|
| April 2018 | $33.5M |
Management
Chief Strategy Officer
Heidi M. Hagen
CTO
Razmik Abnous
Chief Science Officer
Malek Faham
SVP Finance & Operations
Chris Krueger
CO-Founder and Chief Executive Officer
Amy DuRoss
VP, Software Products
Nerses Ohanyan
Co-founder & Director of Marketing
Stephen Ting
Press
GE and the Mayo Clinic back software to bring cancer-fighting gene therapies to market
TechCrunch - Jun, 20 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Vineti or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
